The problem I see with the SARM category is that there is not the body of evidence, either from studies, analysis or crowd-sourced reports that exists for other AAS. They certainly have an affect, however their risk/reward profile is not as well understood. Perhaps that will start to change change since there is apparently an ongoing study looking at Ostarine for muscle retention in people taking GLP-1s, but AAS have decades worth of understanding. It will be interesting to hear your results.